Home/Gero/Yuri Melnichek

YM

Yuri Melnichek

Board Member

Therapeutic Areas

Aging Fibrosis Neurodegeneration

Gero Pipeline

Drug	Indication	Phase
ProtoBind‑Diff Antibody Candidates	Systemic Aging / Resilience	Preclinical
Fibrosis Target Program	Fibrotic Diseases	Preclinical
Chugai Co‑Development Antibody	Age‑Related Immune Dysfunction	Preclinical

Leadership Team at Gero

Peter Fedichev, PhD

CEO, Co‑Founder

Chief Corporate Development Officer, Co‑Founder

Aleksandr Sviridov

Chief Operating Officer

Brian Kennedy, PhD

Independent Director, Board Member

Vadim Gladyshev, PhD

Scientific Advisor

View full Gero profile